Bacteremia in Swedish hematological patients with febrile neutropenia: Bacterial spectrum and antimicrobial resistance patterns

References

• Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, . Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 2007; 30(Suppl 1):S51–9.
   PubMed Web of Science ®Google Scholar
• Nørgaard M, Larsson H, Pedersen G, Schonheyder HC, Sorensen HT. Risk of bacteraemia and mortality in patients with haematological malignancies. Clin Microbiol Infect 2006;12:217–23.
   PubMed Web of Science ®Google Scholar
• Hersh EM, Bodey GP, Nies BA, Freireich EJ. Causes of death in acute leukemia: a ten-year study of 414 patients from 1954–1963. JAMA 1965;193:105–9.
   PubMed Web of Science ®Google Scholar
• Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997;25:247–59.
   PubMed Web of Science ®Google Scholar
• Viscoli C, Bruzzi P, Castagnola E, Boni L, Calandra T, Gaya H, . Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. The International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer 1994;30A:430–7.
   PubMed Web of Science ®Google Scholar
• Viscoli C, Cometta A, Kern WV, Bock R, Paesmans M, Crokaert F, . Piperacillin–tazobactam monotherapy in high-risk febrile and neutropenic cancer patients. Clin Microbiol Infect 2006;12:212–6.
   PubMed Web of Science ®Google Scholar
• Klastersky J. Science and pragmatism in the treatment and prevention of neutropenic infection. J Antimicrob Chemother 1998;41(Suppl D):13–24.
   PubMed Web of Science ®Google Scholar
• Feld R. Bloodstream infections in cancer patients with febrile neutropenia. Int J Antimicrob Agents 2008;32(Suppl 1):S30–3.
   Google Scholar
• Ramphal R. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis 2004;39(Suppl 1):S25–31.
   PubMed Web of Science ®Google Scholar
• Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on Gram-positive and resistant bacteria. Clin Infect Dis 1999; 29:490–4.
   PubMed Web of Science ®Google Scholar
• Cruciani M, Rampazzo R, Malena M, Lazzarini L, Todeschini G, Messori A, . Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 1996;23:795–805.
   PubMed Web of Science ®Google Scholar
• Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case–control study of predisposing factors. Clin Infect Dis 1992;14:1201–7.
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Casari S, Bracchi F, Signorini L, Ravizzola G, Borlenghi E, . Recent increase in enterococci, viridans streptococci, Pseudomonas spp. and multiresistant strains among haematological patients, with a negative impact on outcome. Results of a 3-year surveillance study at a single institution. Scand J Infect Dis 2010;42:324–32.
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Quaresmini G, Casari S, Capucci MA, Micheletti M, Borlenghi E, . Recent changes in bacterial epidemiology and the emergence of fluoroquinolone- resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother 2008;61:721–8.
   PubMed Web of Science ®Google Scholar
• Cherif H, Kronvall G, Bjorkholm M, Kalin M. Bacteraemia in hospitalised patients with malignant blood disorders: a retrospective study of causative agents and their resistance profiles during a 14-year period without antibacterial prophylaxis. Hematol J 2003;4:420–6.
   PubMedGoogle Scholar
• Imran H, Tleyjeh IM, Arndt CA, Baddour LM, Erwin PJ, Tsigrelis C, . Fluoroquinolone prophylaxis in patients with neutropenia: a meta-analysis of randomized placebo-controlled trials. Eur J Clin Microbiol Infect Dis 2008; 27:53–63.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 2006;55:1619–29.
   PubMed Web of Science ®Google Scholar
• Cohen AL, Calfee D, Fridkin SK, Huang SS, Jernigan JA, Lautenbach E, . Recommendations for metrics for multidrug-resistant organisms in healthcare settings: SHEA/HICPAC position paper. Infect Control Hosp Epidemiol 2008;29:901–13.
   PubMed Web of Science ®Google Scholar
• EUCAST European Committee on Antimicrobial Susceptibility Testing. 2011. Available at: http://www.eucast.org/clinical_breakpoints/ (accessed 22 April 2011).
   Google Scholar
• SRGA. Antibiotics SRGf. The Swedish Reference Group for Antibiotics. 2010. Available at: http://www.srga.org/ZONTAB/zontab2b.htm(accessed 22 April 2011).
   Google Scholar
• Cherif H, Kalin M, Bjorkholm M. Antifungal therapy in patients with hematological malignancies: how to avoid overtreatment?Eur J Haematol 2006;77:288–92.
   PubMed Web of Science ®Google Scholar
• Gaytan-Martinez J, Mateos-Garcia E, Sanchez-Cortes E, Gonzalez-Llaven J, Casanova-Cardiel LJ, Fuentes-Allen JL. Microbiological findings in febrile neutropenia. Arch Med Res 2000;31:388–92.
   PubMed Web of Science ®Google Scholar
• Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003;36:1103–10.
   PubMed Web of Science ®Google Scholar
• Sigurdardottir K, Digranes A, Harthug S, Nesthus I, Tangen JM, Dybdahl B, . A multi-centre prospective study of febrile neutropenia in Norway: microbiological findings and antimicrobial susceptibility. Scand J Infect Dis 2005;37:455–64.
   PubMed Web of Science ®Google Scholar
• Kern WV, Andriof E, Oethinger M, Kern P, Hacker J, Marre R. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 1994;38:681–7.
   PubMed Web of Science ®Google Scholar
• Razonable RR, Litzow MR, Khaliq Y, Piper KE, Rouse MS, Patel R. Bacteremia due to viridans group streptococci with diminished susceptibility to levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Clin Infect Dis 2002;34:1469–74.
   PubMed Web of Science ®Google Scholar
• Carratala J, Alcaide F, Fernandez-Sevilla A, Corbella X, Linares J, Gudiol F. Bacteremia due to viridans streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer. Clin Infect Dis 1995;20: 1169–73.
   PubMed Web of Science ®Google Scholar
• Kjellander C, Bjorkholm M, Cherif H, Kalin M, Giske CG. Low all-cause mortality and low occurrence of antimicrobial resistance in hematological patients with bacteremia receiving no antibacterial prophylaxis: a single-center study. Eur J Haematol 2012;88:422–30.
   PubMed Web of Science ®Google Scholar
• Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, . Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005;353:988–98.
   PubMed Web of Science ®Google Scholar
• Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, . Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005;353:977–87.
   PubMed Web of Science ®Google Scholar
• Trimethoprim–sulfamethoxazole in the prevention of infection in neutropenic patients. EORTC International Antimicrobial Therapy Project Group. J Infect Dis 1984; 150:372–9.
   PubMedGoogle Scholar
• Auner HW, Sill H, Mulabecirovic A, Linkesch W, Krause R. Infectious complications after autologous hematopoietic stem cell transplantation: comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma. Ann Hematol 2002;81:374–7.
   PubMed Web of Science ®Google Scholar
• Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328–40.
   PubMed Web of Science ®Google Scholar
• Prat C, Sancho JM, Dominguez J, Xicoy B, Gimenez M, Ferra C, . Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. Leuk Lymphoma 2008;49:1752–61.
   PubMed Web of Science ®Google Scholar
• Juutilainen A, Hamalainen S, Pulkki K, Kuittinen T, Nousiainen T, Jantunen E, . Biomarkers for bacteremia and severe sepsis in hematological patients with neutropenic fever: multivariate logistic regression analysis and factor analysis. Leuk Lymphoma 2011;52:2349–55.
   PubMed Web of Science ®Google Scholar
• Bates DW, Pruess KE, Lee TH. How bad are bacteremia and sepsis? Outcomes in a cohort with suspected bacteremia. Arch Intern Med 1995;155:593–8.
   PubMedGoogle Scholar
• Wilchesky M, Tamblyn RM, Huang A. Validation of diagnostic codes within medical services claims. J Clin Epidemiol 2004;57:131–41.
   PubMed Web of Science ®Google Scholar